Geode Capital Management
LTGO

Geode Capital Management’s Latigo Biotherapeutics LTGO Stock Holding History

Geode Capital Management’s Portfolio LTGO Stock Details LTGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.68M Buy
+220,175
New +$4.65M ﹤0.01% 2991

Other funds holding LTGO

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Jacobi Capital Management
Jacobi Capital Management Pittston, Pennsylvania $2.11B AUM 19.6% 1-Year Est. Return

Geode Capital Management's LTGO Position: Q3 2026 in Review

Geode Capital Management opened a new position in Latigo Biotherapeutics (LTGO) in Q3 2026: 220,175 shares worth $3.68M. The stake represents ﹤0.01% of the portfolio and ranks #2991 among its holdings.

6 funds tracked by Wall St. Rank hold LTGO as of Q3 2026.

  • Geode Capital Management held 220,175 shares of Latigo Biotherapeutics worth $3.68M as of Q3 2026.
  • Latigo Biotherapeutics was a new Geode Capital Management position in Q3 2026.
  • Latigo Biotherapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #2991 holding.
  • 6 funds tracked by Wall St. Rank held Latigo Biotherapeutics as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.